Keuangan Amgen Inc. (AMGN)
NASDAQ · Healthcare · Drug Manufacturers - General · Karyawan: 31.500 · CEO: Robert A. Bradway
- Harga
- $466,01 +1,15%
- Kapitalisasi pasar
- $252 M
- Nilai perusahaan
- $295 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-05
- Laporan berikutnya
- 2026-11-03 Estimasi EPS: $5,79
Pendapatan (TTM)$38,1 M+9,2% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)33,2%+9,7 poin vs tahun laluLaba operasional: $12,6 M
Laba bersih (TTM)$8,74 M+32,1% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$10,2 M-4,1% vs tahun laluCapex: $2,3 M
EPS dilusian (TTM)$16,09+31,6% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$43,3 M+10,1% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $252 M EV $295 M
- Pendapatan
- $38,1 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +6% Konsensus FY2026
- Margin laba
- 22,9% Laba bersih / pendapatan, TTM
- P/E
- 28,7× Forward 20,2× (FY2026)
- P/S
- 6,6× Harga / penjualan, TTM
- EV / EBITDA
- 16,8× TTM
- Arus kas bebas
- $10,2 M 12 bulan terakhir
- Laba bersih
- $8,74 M 12 bulan terakhir
- Estimasi pendapatan
- $39 M Konsensus FY2026
- Laba
- 2026-11-03 Estimasi pendapatan: $10,1 M
- Dividen
- $9,94 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-04): pendapatan melampaui 6,7%, EPS melampaui 11,9%Pendapatan $10,1 M vs $9,43 M yang diharapkan (+6,7%); EPS $6,29 vs $5,62 (+11,9%).
- Pertumbuhan pendapatan stabil: 9,7% yoyPendapatan Q2 '26: $10,1 M, rata-rata empat kuartal sebelumnya: 9,1%.
- Margin operasional 33,2% (TTM), dibanding tahun lalu: +9,7 poinLaba operasional tumbuh 54,6%, pendapatan tumbuh 9,2%.
- 23,0% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $10,3 M vs laba operasional $12,6 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 6,0% dari pendapatan (tahun lalu 4,0%)$2,3 M diinvestasikan dalam 4 kuartal terakhir (+63,6% dibanding tahun sebelumnya). Arus kas bebas: $10,2 M = 116,4% dari laba bersih.
- $5,29 M dikembalikan ke pemegang saham = 51,9% dari arus kas bebasBuyback: $0 (tahun lalu $200 jt), dividen: $5,29 M, kompensasi saham: $492 jt (TTM).
- Jumlah saham dilusian naik dalam setahun: 0,6%Saham dilusian pada Q2 '26: 544 jt, setahun sebelumnya: 541 jt.
- Utang neto: $43,3 MKas + investasi jangka pendek: $14 M, utang termasuk sewa: $57,3 M; tahun lalu utang neto: $48,2 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $10,1 M | $9,17 M | +9,7% |
| Margin kotor | 72,0% | 67,2% | +4,9 poin |
| Laba operasional | $3,51 M | $2,64 M | +32,9% |
| Margin operasional | 35,0% | 28,8% | +6,1 poin |
| Laba bersih | $2,38 M | $1,43 M | +65,9% |
| EPS dilusian | $4,37 | $2,65 | +64,9% |
| Arus kas operasional | $4 M | $2,28 M | +75,5% |
| Capex | $513 jt | $369 jt | +39,0% |
| Arus kas bebas | $3,49 M | $1,91 M | +82,6% |
| R&D | $1,87 M | $1,74 M | +7,1% |
| Kompensasi berbasis saham | $165 jt | $157 jt | +5,1% |
Dilaporkan vs konsensus
2026-08-04| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $10,1 M | $9,43 M | +6,7% |
| EPS (basis konsensus) | $6,29 | $5,62 | +11,9% |
Dari laporan 2026-08-04 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Other Products | – | – | – | – | – | |
| Other products | $1,7 M | – | 16,9% | – | – | |
| Prolia | $759 jt | -32,4% | 7,5% | – | – | |
| ENBREL | $580 jt | -4,0% | 5,8% | – | – | |
| Product and Service, Other | – | – | – | – | – | |
| Repatha | $953 jt | – | 9,5% | – | – | |
| Repatha (evolocumab) | – | – | – | – | – | |
| EVENITY | $714 jt | +37,8% | 7,1% | – | – | |
| Otezla | $491 jt | -20,6% | 4,9% | – | – | |
| TEPEZZA | $576 jt | +14,1% | 5,7% | – | – | |
| XGEVA | $352 jt | -33,8% | 3,5% | – | – | |
| Other revenues | $517 jt | – | 5,1% | – | – | |
| TEZSPIRE | $486 jt | +42,1% | 4,8% | – | – | |
| BLINCYTO | $472 jt | +22,9% | 4,7% | – | – | |
| Nplate | $430 jt | +16,5% | 4,3% | – | – | |
| KRYSTEXXA | $400 jt | +14,6% | 4,0% | – | – | |
| Kyprolis | – | – | – | – | – | |
| Aranesp | $352 jt | -1,9% | 3,5% | – | – | |
| Vectibix | $338 jt | +10,8% | 3,4% | – | – | |
| UPLIZNA | $335 jt | – | 3,3% | – | – | |
| KYPROLIS | $314 jt | – | 3,1% | – | – | |
| IMDELLTRA/IMDYLLTRA | $288 jt | – | 2,9% | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $6,99 M | +10,5% | 73,3% | – | – | |
| Non-US | $2,55 M | +4,1% | 26,7% | – | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $12,5 M
- Capex
- -$2,3 M
- Buyback
- $0
- Dividen
- -$5,29 M
- Akuisisi
- -$53 jt
- Utang neto diterbitkan
- $1,32 M
- Kompensasi berbasis saham
- $492 jt
- Arus kas bebas
- $10,2 M
- Dikembalikan ke pemegang saham / FCF
- 51,9%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 28,7× | 24,7× | 21,6× – 34,2× |
| EV / EBITDA | 16,8× | 13,8× | 13,1× – 14,2× |
| EV / Penjualan | 7,7× | 6,3× | 5,7× – 7,4× |
| Harga / FCF | 24,8× | 17,5× | 13,6× – 21,7× |
| Harga / Nilai buku | 21,5× | 25,4× | 19,1× – 38,6× |
| Imbal hasil FCF | 4,0% | 5,9% | 4,6% – 7,4% |
| Imbal hasil modal yang diinvestasikan | 14,2% | 12,2% | 8,4% – 16,7% |
| Imbal hasil ekuitas | 89,3% | 106,7% | 69,6% – 179,0% |
Analis
Target konsensus $403,79 (-13,4%)
rentang $230,00 – $500,00 · peringkat Buy
Beli kuat0
Beli22
Tahan16
Jual3
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $39 M | +6,1% | $23,06 | +62,0% | 20,2× | 19 |
| FY2027 | $40,5 M | +3,8% | $24,51 | +6,3% | 19,0× | 19 |
| FY2028 | $41,9 M | +3,4% | $25,94 | +5,8% | 18,0× | 11 |
| FY2029 | $43,5 M | +4,0% | $27,75 | +7,0% | 16,8× | 4 |
| FY2030 | $45,5 M | +4,5% | $29,74 | +7,2% | 15,7× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 237 angka yang ditandai Amgen Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $2,87 M | $3,01 M | -4,8% | $2,37 M | $1,91 M | +24,1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $10,2 M | $8,7 M | +17,5% | $9,57 M | $6,78 M | +41,1% |
| Accrued Income Taxes, Current | $379 jt2025-12-31 | $2,58 M | -85,3% | $379 jt | $2,58 M | -85,3% |
| Accrued Liabilities, Current | $17,2 M | $15 M | +14,4% | $18,5 M | $17,6 M | +5,0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $9,4 M | $10,8 M | -13,0% | $11,1 M | $10,4 M | +7,0% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$119 jt | -$544 jt | +78,1% | -$258 jt | -$66 jt | -290,9% |
| Advertising Expense | – | – | – | $963 jt | $987 jt | -2,4% |
| Amortization of Intangible Assets | $890 jt | $1,1 M | -19,1% | $4,3 M | $4,8 M | -10,4% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $165 jt | $157 jt | +5,1% | $494 jt | $530 jt | -6,8% |
| Assets | $95,6 M | $87,9 M | +8,8% | $90,6 M | $91,8 M | -1,4% |
| Assets, Current | $35 M | $26,7 M | +30,8% | $29,1 M | $29 M | +0,1% |
| Assets, Fair Value Disclosure | $19,6 M | $12,5 M | +56,8% | $14,9 M | $16,1 M | -7,3% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | – | – | – | -$6 jt | $18 jt | -133,3% |
| Business Combination, Contingent Consideration, Liability | $171 jt | $90 jt | +90,0% | $161 jt | $106 jt | +51,9% |
| Capitalized Contract Cost, Net | $272 jt2025-12-31 | $227 jt | +19,8% | $272 jt | $227 jt | +19,8% |
| Cash | $574 jt | $542 jt | +5,9% | $604 jt | $487 jt | +24,0% |
| Cash and Cash Equivalents, at Carrying Value | $14 M | $8,03 M | +74,3% | $9,13 M | $12 M | -23,8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $14 M | $8,03 M | +74,3% | $9,13 M | $12 M | -23,8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $1,95 M | -$782 jt | +349,5% | -$2,84 M | $1,03 M | -376,4% |
| Commercial Paper | $02025-12-31 | $0 | – | $0 | $0 | – |
| Common Stock, Dividends, Per Share, Declared | $0,00 | $2,38 | -100,0% | $9,66 | $9,13 | +5,8% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 2,75 M | 2,75 M | 0,0% | 2,75 M | 2,75 M | 0,0% |
| Common Stock, Shares, Outstanding | 541 jt | 538 jt | +0,4% | 539 jt | 537 jt | +0,4% |
| Common Stocks, Including Additional Paid in Capital | $34,1 M | $33,7 M | +1,2% | $34 M | $33,5 M | +1,5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $2,45 M | $1,12 M | +118,6% | $7,52 M | $4,31 M | +74,3% |
| Cost of Goods and Services Sold | $2,81 M | $3,01 M | -6,6% | $12 M | $12,9 M | -6,4% |
| Costs and Expenses | $6,54 M | $6,52 M | +0,3% | $27,7 M | $26,2 M | +5,8% |
| Current Federal Tax Expense (Benefit) | – | – | – | $959 jt | $965 jt | -0,6% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $971 jt | $759 jt | +27,9% |
| Current Income Tax Expense (Benefit) | – | – | – | $1,97 M | $1,76 M | +11,8% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $35 jt | $33 jt | +6,1% |
| Debt Instrument, Face Amount | $4 M2026-03-31 | – | – | $4,5 M2017-12-31 | $6,7 M | -32,8% |
| Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $1,32 M | $1,33 M | -1,1% | $1,31 M | $1,36 M | -4,0% |
| Debt Securities, Available-for-sale | $13,4 M | $7,49 M | +79,2% | $8,53 M | $11,5 M | -25,8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $13,4 M | $7,49 M | +79,2% | $8,53 M | $11,5 M | -25,8% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$465 jt | -$860 jt | +45,9% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$242 jt | -$360 jt | +32,8% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$700 jt | -$1,24 M | +43,5% |
| Deferred Income Tax Liabilities, Net | $1,3 M | $1,39 M | -6,1% | $1,37 M | $1,62 M | -15,5% |
| Deferred Income Taxes and Tax Credits | -$291 jt | -$422 jt | +31,0% | -$721 jt | -$1,23 M | +41,3% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $7 jt | -$18 jt | +138,9% |
| Deferred Tax Assets, Equity Method Investments | $02025-12-31 | $1 jt | -100,0% | $0 | $1 jt | -100,0% |
| Deferred Tax Assets, Gross | $6,92 M2025-12-31 | $6 M | +15,5% | $6,92 M | $6 M | +15,5% |
| Deferred Tax Assets, Net | $2,39 M2025-12-31 | $1,64 M | +45,7% | $2,39 M | $1,64 M | +45,7% |
| Deferred Tax Assets, Net of Valuation Allowance | $5,62 M2025-12-31 | $4,98 M | +13,0% | $5,62 M | $4,98 M | +13,0% |
| Deferred Tax Assets, Other | $349 jt2025-12-31 | $361 jt | -3,3% | $349 jt | $361 jt | -3,3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $138 jt2025-12-31 | $130 jt | +6,2% | $138 jt | $130 jt | +6,2% |
| Deferred Tax Assets, Tax Deferred Expense, Other | $218 jt2025-12-31 | $200 jt | +9,0% | $218 jt | $200 jt | +9,0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $890 jt2025-12-31 | $693 jt | +28,4% | $890 jt | $693 jt | +28,4% |
| Deferred Tax Assets, Valuation Allowance | $1,3 M2025-12-31 | $1,02 M | +27,5% | $1,3 M | $1,02 M | +27,5% |
| Deferred Tax Liabilities, Financing Arrangements | $260 jt2025-12-31 | $264 jt | -1,5% | $260 jt | $264 jt | -1,5% |
| Deferred Tax Liabilities, Gross | $3,24 M2025-12-31 | $3,34 M | -3,0% | $3,24 M | $3,34 M | -3,0% |
| Deferred Tax Liabilities, Intangible Assets | $2,07 M2025-12-31 | $2,57 M | -19,7% | $2,07 M | $2,57 M | -19,7% |
| Deferred Tax Liabilities, Inventory | $28 jt2025-12-31 | $114 jt | -75,4% | $28 jt | $114 jt | -75,4% |
| Deferred Tax Liabilities, Investments | $422 jt2025-12-31 | $0 | – | $422 jt | $0 | – |
| Deferred Tax Liabilities, Other | $271 jt2025-12-31 | $244 jt | +11,1% | $271 jt | $244 jt | +11,1% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $192 jt2025-12-31 | $143 jt | +34,3% | $192 jt | $143 jt | +34,3% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01